J & J Completes Sale Of Breast Cancer Unit

Ethicon Endo-Surgery, a unit of Johnson & Johnson, said Monday it completed the sale of its breast cancer business to Devicor Medical Products.

NEW YORK (AP) -- Ethicon Endo-Surgery, a unit of Johnson & Johnson, said Monday it completed the sale of its breast cancer business to Devicor Medical Products.

In March, Ethicon said it received an offer from Devicor, but did not disclose the price. Ethicon's breast care unit sells products used by doctors to help diagnose breast cancer.

Devicor is a portfolio company of private equity investment firm GTCR Golder Rauner LLC. About 300 employees supporting the breast cancer business will transfer to Devicor.

Shares of Johnson & Johnson, based in New Brunswick, N.J., fell 13 cents to $60.41 in morning trading.

More in Economics